Growth Hormone Peptides

• Glycoprotein Hormone (hCG): 237-amino acid heterodimer (α-subunit 92 aa + β-subunit 145 aa), ≥95% purity by SDS-PAGE, 5,000 IU per vial
• LHCGR Biased Agonism: cAMP/PKA steroidogenic signaling, EC₅₀ 107 pM — 5-fold more potent than LH for cAMP production
• Reproductive Endocrinology Research: GPCR signaling, steroidogenesis, and endometrial biology investigation

• Master Reproductive Regulator: C-terminal decapeptide (YNWNSFGLRF-NH2), ≥95% purity
• KISS1R/GPR54 Agonist: 8-fold higher receptor affinity than kisspeptin-54 (Ki = 0.042 nM)
• GnRH Pulse Generator: Most potent GnRH neuron stimulator, 4-minute human plasma half-life

PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic, stabilized form of the 24-amino acid MGF E-domain peptide derived from the IGF-1Ec splice variant. Research shows it activates satellite cells, promotes myoblast proliferation via MAPK-ERK1/2 signaling, and demonstrates neuroprotective effects through PKCε/Nrf2/HO-1 pathways.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum sagittis orci ac odio dictum tincidunt.

• Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
• Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
• Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use